Anthropic announced that Novartis CEO Vas Narasimhan has joined its board of directors. The appointment signals the AI company's deepening commitment to healthcare and life sciences applications.
Narasimhan's addition to Anthropic's board comes as the Claude chatbot maker expands its presence in the pharmaceutical and biotech sectors. Earlier this month, Anthropic acquired biotech startup Coefficient Bio for approximately $400 million.
The move reflects growing interest from major healthcare companies in artificial intelligence capabilities. Narasimhan brings decades of experience in pharmaceutical leadership and drug development, positioning him to guide Anthropic's healthcare initiatives.
Anthhropic has been building specialized tools for life sciences research, leveraging Claude's language capabilities for tasks including drug discovery support and scientific analysis. The Coefficient Bio acquisition accelerated these efforts by bringing in specialized biotech expertise.
Board appointments from pharmaceutical executives represent a significant vote of confidence from the healthcare industry in Anthropic's technology and direction. The partnership may also facilitate future collaborations between Anthropic and Novartis on AI applications in drug development and healthcare.
Israel-based Hemispheric secured $52 million in funding for its AI model that analyzes non-invasive brain activity measurements and converts them into quantitative diagnostic metrics.
Anthropic and Blackstone are backing Ode, a new venture that embeds AI engineers directly inside enterprises. The bet signals a shift in where the next trillion dollars in AI value may be created: not in building models, but in implementing them.
Spectro Cloud, an AI infrastructure company focused on managing token costs, secured $100 million in Series D funding at a valuation exceeding $1 billion. The raise marks significant growth from the company's $750 million valuation in 2024.
Startups like Altur are deploying AI chatbots to handle debt collection calls, automating a process traditionally done by humans. Y Combinator has backed six debt collection and settlement startups over the past six years.